Synthetic biology has long promised alternatives to human blood components. Examine the scientific and ethical challenges in developing artificial haemoglobin substitutes.

Haemoglobin — the iron-bearing protein that ferries oxygen from lungs to tissues — has been a synthetic-biology target since 1976, when Columbia University researchers reported that a haemoglobin molecule could be taken apart and reassembled, removing a key barrier to man-made haemoglobin [1]. Fifty years on, the promise remains only partly realised, because the obstacles are as much ethical as technical.

Scientific challenges

• Molecular stability: synthetic globin chains must bind stably to heme, the iron-containing component that actually carries oxygen; without stable binding the chains disintegrate [1].
• Functional limits: even the 1976 researchers cautioned that artificial haemoglobin cannot replace whole-blood transfusion or sustain a trauma patient indefinitely without replenishment [1] — it carries oxygen but not clotting or immune functions.
• Disease modelling: the stated scientific pay-off is comparing synthetic normal haemoglobin with synthetic sickle-cell haemoglobin (HbS), produced by a mutation in the HBB gene that renders red cells rigid and sickle-shaped [1][2].
• Scale and burden: with 7.74 million people living with sickle-cell disease globally and about 515,000 affected births a year [2], laboratory success must translate into affordable mass therapy.

Ethical and governance challenges

• Equity of access: costly blood substitutes risk bypassing the tribal-majority populations who bear India's SCD burden — the very group targeted by the National Sickle Cell Anaemia Elimination Mission (NSCAEM), launched on 1 July 2023 at Shahdol [3].
• Screening, consent and stigma: NSCAEM's screening of the 0–40 age group has identified 16.7 lakh carriers alongside 2.15 lakh diagnosed cases [4]; genetic data of this scale demands counselling, privacy safeguards and protection from marital and social stigma.
• Research priorities: exotic substitutes must not crowd out proven, low-cost prevention, counselling and transfusion services.

Artificial haemoglobin is therefore best seen not as a substitute for blood, but as a research and adjunct tool. Aligning it with NSCAEM's goal of eliminating sickle-cell disease as a public health problem by 2047 [3], and with SDG-3 on health for all, would make synthetic biology serve equity rather than exclusivity.